Armata Pharmaceuticals, Inc. ARMP
2.98 USD -0.19 (-5.99%)
Regular-session close
3.25 +0.27 +9.06%
After hours · Nov 19, 4:00 PM ET
2.85 Day range 3.23
2.40 52-week range 14.98
- YTD
- -52.55%
- 1 year
- -59.18%
News
zacks.com Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Beats Revenue Estimates Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.42 per share a year ago.benzinga.com Armata Pharmaceuticals Q3 EPS $(0.24) Beats $(0.56) Estimate, Sales $3.171M Beat $450.000K Estimate Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.56) by 57.14 percent. This is a 67.57 percent increase over losses…
prnewswire.com Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update LOS ANGELES, Nov. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
prnewswire.com Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041 LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE…
benzinga.com Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program Armata Pharmaceuticals Inc. (AMEX:ARMP) shares are trading lower on Wednesday as traders digest additional non-dilutive funding tied to its lead bacteriophage program.
prnewswire.com Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total…
prnewswire.com Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates Controlled manufacturing reproducibly maintains defined genetic diversity across AP-SA02 clinical drug product lots Oral presentation scheduled for today Monday, Sept. 21, 2026 at the 20 th…
prnewswire.com Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies…
prnewswire.com Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference LOS ANGELES, Sept. 10, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
prnewswire.com Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials LOS ANGELES, Sept. 3, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
prnewswire.com Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
zacks.com Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar? Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…
prnewswire.com Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting Four AP-SA02 engineering runs completed; clinical trial material production is the next…
prnewswire.com Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals,…
prnewswire.com Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the…
prnewswire.com Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the…
prnewswire.com Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02…
prnewswire.com Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP)…
prnewswire.com Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
prnewswire.com Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
prnewswire.com Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of…
